Literature DB >> 12429347

CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes.

Namrata Bahadur1, Julian B S Leathart, Elaine Mutch, Dorothy Steimel-Crespi, Stuart A Dunn, Ron Gilissen, Jos Van Houdt, Jan Hendrickx, Geert Mannens, Hilde Bohets, Faith M Williams, Martin Armstrong, Charles L Crespi, Ann K Daly.   

Abstract

Published cDNA sequences suggest the existence of non-synonymous single nucleotide polymorphisms in the cytochrome P450 CYP2C8. To determine whether these polymorphisms could be confirmed in a Caucasian population and to investigate whether additional polymorphisms occur in the coding and upstream regions of this gene, we screened for previously described and for novel polymorphisms using PCR-RFLP and SSCP analysis. We confirmed the existence of two of the previously detected polymorphisms which give rise to the amino acid substitutions I264M and K399R, respectively, but failed to detect three others in our population. We also confirmed that a recently identified polymorphism (R139K) is linked to K399R (CYP2C8*3) in our study population. The allele frequencies for the I264M (CYP2C8*4 allele) and the CYP2C8*3 allele were 0.075 and 0.15, respectively. Three novel polymorphisms (T-370G, C-271A and T1196C/L390S) were also detected with the upstream polymorphisms showing allele frequencies of 0.061 and 0.196, respectively, but the L390S polymorphism detected only in a single subject. An additional single subject was heterozygous for a polymorphism recently described in African-Americans (A805T; CYP2C8*2 allele). The functional significance of the two upstream polymorphisms and the CYP2C8*3 and CYP2C8*4 alleles was investigated in human liver microsomes. Samples heterozygous for CYP2C8*3 showed significantly lower paclitaxel 6alpha-hydroxylase activity compared with wild-type samples. Median activity associated with CYP2C8*4 also appeared lower than the wild-type but the difference was not significant. There was no evidence that either upstream polymorphism gave rise to altered CYP2C8 expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429347     DOI: 10.1016/s0006-2952(02)01354-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  60 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.

Authors:  Tanja Busk Bidstrup; Per Damkier; Anette Kristensen Olsen; Marianne Ekblom; Anders Karlsson; Kim Brøsen
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

3.  CYP2C8 polymorphism frequencies among malaria patients in Zanzibar.

Authors:  I Cavaco; J Strömberg-Nörklit; A Kaneko; M I Msellem; M Dahoma; V L Ribeiro; A Bjorkman; J P Gil
Journal:  Eur J Clin Pharmacol       Date:  2005-01-27       Impact factor: 2.953

Review 4.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

5.  Genetic polymorphisms of CYP2C8 in the Czech Republic.

Authors:  Kristina Pechandova; Helena Buzkova; Olga Matouskova; Frantisek Perlik; Ondrej Slanar
Journal:  Genet Test Mol Biomarkers       Date:  2012-02-07

Review 6.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.

Authors:  Noelia Nebot; Severine Crettol; Fabrizio d'Esposito; Bruce Tattam; David E Hibbs; Michael Murray
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

8.  CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Craig R Lee; Kari E North; Molly S Bray; David J Couper; Gerardo Heiss; Darryl C Zeldin
Journal:  Pharmacogenet Genomics       Date:  2007-05       Impact factor: 2.089

9.  Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.

Authors:  P Dorado; I Cavaco; M C Cáceres; R Piedade; V Ribeiro; A Llerena
Journal:  Eur J Clin Pharmacol       Date:  2008-06-12       Impact factor: 2.953

10.  Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.

Authors:  Paulo Arnaldo; Ricardo Estevão Thompson; Márcia Quinhones Lopes; Philip Noel Suffys; Adalberto Rezende Santos
Journal:  Malays J Med Sci       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.